Egrifta (Tesamorelin) Cannabis Interaction Profile

What Is Tesamorelin and Why Does the GH Axis Matter?

Tesamorelin (brand name Egrifta SV) is a 44-amino-acid GHRH analogue approved by the FDA in 2010 for reducing excess visceral adipose tissue (VAT) in adults with HIV-associated lipodystrophy [1]. It binds pituitary GHRH receptors, which triggers pulsatile GH release. Downstream, the liver converts that GH signal into insulin-like growth factor-1 (IGF-1), and IGF-1 drives lipolysis in visceral fat depots [2].

How Tesamorelin Changes the GH Pulse

In the key Phase III UCSF trial (N=412), tesamorelin 2 mg SC daily for 26 weeks raised IGF-1 by roughly 181 ng/mL above placebo and reduced trunk fat by 17.8% vs. 2.4% for placebo (P<0.001) [3]. The drug does not replace GH directly. It amplifies the natural GH pulse pattern, which means anything that suppresses the somatotroph cells between doses will directly reduce therapeutic benefit.

The IGF-1 Signal as a Surrogate Marker

Clinicians typically monitor IGF-1 at baseline and at 3-month intervals while on tesamorelin [1]. A declining or flat IGF-1 response despite consistent dosing is the clearest early signal that the pituitary GH axis is being suppressed by an external factor, whether that is glucocorticoid use, untreated hypothyroidism, or, as discussed below, regular cannabis exposure [4].

How Cannabis Affects the Hypothalamic-Pituitary-GH Axis

Cannabis contains more than 100 cannabinoids. Delta-9-tetrahydrocannabinol (THC) is the main psychoactive compound and the one with the most documented neuroendocrine effects [5]. Cannabidiol (CBD) has distinct pharmacology, though its interaction data with GHRH pathways remain sparse.

Acute GH Suppression With THC

A controlled human study published in Psychopharmacology administered intravenous THC to healthy volunteers and measured GH every 20 minutes for 3 hours. Serum GH fell significantly in the first 90 minutes post-dose compared with placebo [6]. The proposed mechanism is CB1 receptor activation in the hypothalamus, which reduces GHRH release and simultaneously increases somatostatin tone, the primary inhibitor of GH secretion [7].

Because tesamorelin works by supplying exogenous GHRH at the pituitary receptor level, an increase in somatostatin tone from cannabis may partially block the downstream GH pulse even when tesamorelin occupies the receptor [8]. This is a pharmacodynamic interaction, not a metabolic one.

Chronic Cannabis Use and the GH Axis

Chronic heavy cannabis users show blunted GH responses to provocative stimuli compared with non-users in observational data [9]. One study in Drug and Alcohol Dependence reported that daily cannabis users had mean basal GH levels approximately 40% lower than matched controls, though sample sizes were modest (N=48) [10]. These findings have not been replicated in large prospective cohorts, so the magnitude of chronic suppression is uncertain.

Cortisol and the Somatotroph

Acute cannabis use raises cortisol, an effect mediated through the hypothalamic-pituitary-adrenal axis [11]. Elevated cortisol directly inhibits GH secretion at the somatotroph level and reduces hepatic IGF-1 output independently [12]. For a patient on tesamorelin who is attempting to raise IGF-1 toward the mid-normal range, repeated cortisol spikes from cannabis use create a pharmacodynamic headwind.

Insulin Resistance: A Metabolic Crossroads

Tesamorelin improves visceral fat by raising GH and IGF-1. GH is intrinsically diabetogenic at high levels, a reason the FDA label for Egrifta SV warns that glucose monitoring is required [1]. Cannabis adds a separate and independent layer of metabolic complexity.

Cannabis and Glucose Regulation

Acute THC intoxication is associated with transient hyperglycemia in some studies, while chronic low-dose cannabis users paradoxically show lower fasting insulin in cross-sectional data from NHANES [13]. The direction of the glucose effect appears to depend on frequency, dose, and cannabinoid ratio. A 2016 systematic review in Diabetes Care (covering 15 studies) concluded that evidence is insufficient to make definitive claims about cannabis and glycemic control, but noted that acute high-dose THC may impair insulin signaling [14].

Compounding Tesamorelin's Glucose Warning

The Egrifta SV prescribing information explicitly states: "Tesamorelin may cause glucose intolerance. Monitor for glucose abnormalities and consider the benefits and risks in patients with diabetes or risk factors for diabetes" [1]. When cannabis use sits on top of this existing glucometabolic risk, the combined effect on HbA1c and fasting glucose should be tracked at intervals no longer than 3 months for patients who use cannabis regularly.

Practical Monitoring Table

| Parameter | Baseline | 3 Months | 6 Months | Notes | |---|---|---|---|---| | IGF-1 (ng/mL) | Yes | Yes | Yes | Target: age- and sex-adjusted mid-normal | | Fasting glucose (mg/dL) | Yes | Yes | Yes | Tesamorelin label requirement | | HbA1c (%) | Yes | Optional | Yes | Required if diabetes present | | Trunk fat (DEXA or CT) | Yes | Optional | Yes | Primary efficacy endpoint | | Cortisol (AM) | Optional | If IGF-1 flat | If IGF-1 flat | Rule out secondary suppression |

Pharmacokinetic Considerations: Does Cannabis Change Tesamorelin Levels?

Tesamorelin is a peptide administered subcutaneously. It does not undergo hepatic CYP450 metabolism in the traditional small-molecule sense. Peptides are proteolytically cleaved in plasma and at tissue receptor sites [2]. Cannabis, by contrast, is primarily metabolized by CYP2C9 and CYP3A4, with CBD additionally inhibiting CYP2C19 and CYP3A4 at higher doses [15].

CYP Interaction: Low Direct Risk for Tesamorelin

Because tesamorelin is not a CYP substrate, CBD's known CYP3A4 and CYP2C19 inhibitory effects do not directly alter tesamorelin plasma exposure [15]. This is meaningfully different from small-molecule drugs like warfarin (CYP2C9 substrate) or certain HIV antiretrovirals where cannabis co-administration raises real pharmacokinetic concern [16].

The FDA drug interaction guidance for peptide hormones generally does not flag CYP-mediated interactions as a primary concern [17]. The interaction risk with cannabis is therefore pharmacodynamic, driven by neuroendocrine axis modulation, not pharmacokinetic, driven by altered drug exposure.

Antiretroviral Context in HIV Patients

Most tesamorelin patients are also on antiretroviral therapy (ART). Cannabis is used by a notable proportion of people living with HIV; the CDC estimated cannabis use among PLWH at roughly 34% in behavioral surveillance data [18]. Several ART agents, particularly ritonavir-boosted regimens, are themselves strong CYP3A4 inhibitors and may raise THC and CBD plasma levels through reduced first-pass metabolism [16]. This is not a tesamorelin-specific interaction, but it affects the overall safety picture for the patient panel most likely to receive Egrifta.

What the Egrifta Label Actually Says About Drug Interactions

The current Egrifta SV prescribing information (Theratechnologies, 2023 revision) lists the following interaction categories [1]:

• Glucocorticoids: may attenuate GH response (same mechanism as endogenous cortisol elevation from cannabis)
• Drugs metabolized by CYP450: tesamorelin may modestly induce CYP3A4, potentially lowering levels of CYP3A4-sensitive ART drugs
• Insulin and antidiabetic agents: dose adjustment may be needed if glucose worsens

Cannabis does not appear in the label by name. That omission reflects the absence of dedicated clinical trial data, not a regulatory finding that the combination is safe.

A Clinical Decision Framework for Cannabis-Using Patients on Tesamorelin

Prescribers encountering a patient who wants to continue cannabis while starting or maintaining tesamorelin can use the following stepwise approach. This framework is based on the pharmacodynamic evidence above and standard endocrine monitoring principles from the Endocrine Society's 2011 GH Deficiency Clinical Practice Guideline [4].

Step 1: Characterize Cannabis Use Precisely

Ask about cannabinoid type (THC-dominant, CBD-dominant, or balanced), route (smoked, vaped, edibles), frequency (daily, weekly, occasional), and dose in approximate mg of THC per session. Occasional use (less than once weekly) carries a lower theoretical GH-axis burden than daily high-THC inhalation.

Step 2: Establish a Solid IGF-1 Baseline

Draw IGF-1 before starting tesamorelin and again at 3 months. If IGF-1 has not risen by at least 50 ng/mL above baseline after 3 months of consistent dosing, cannabis-related somatostatin-driven suppression is one differential to consider alongside non-compliance, malnutrition, or comorbid hypothyroidism [4].

Step 3: Time Cannabis Use Away From Injection if Possible

There is no published data on injection timing versus cannabis timing in humans. However, because GH pulses triggered by tesamorelin occur within 1 to 2 hours of injection [2], avoiding cannabis for at least 3 hours before and 2 hours after the daily injection may reduce the overlap of peak THC exposure with peak GHRH receptor stimulation. This is theoretical guidance only.

Step 4: Tighten Glucose Monitoring

Any patient combining tesamorelin (which raises GH, a counter-regulatory hormone) with cannabis (which may impair insulin signaling acutely) should have fasting glucose checked at least every 3 months [1][14].

Step 5: Reassess VAT Reduction at 26 Weeks

Tesamorelin's key trials used DEXA or CT-measured trunk fat as the primary endpoint at 26 weeks [3]. If VAT has not decreased meaningfully and IGF-1 remains suboptimal, the prescriber should weigh whether cannabis cessation is warranted before concluding tesamorelin is ineffective.

Cannabis and HIV-Associated Lipodystrophy: Background Interaction

HIV-associated lipodystrophy itself involves insulin resistance, dyslipidemia, and regional fat redistribution [19]. Cannabis use among PLWH is sometimes reported as an appetite stimulus and a tool for nausea management in the context of ART [20]. The prescriber should weigh the therapeutic reasons a patient uses cannabis (pain, nausea, sleep, anxiety) against the metabolic and neuroendocrine risks when co-administered with tesamorelin.

A 2020 observational study in AIDS and Behavior (N=222 PLWH) found that cannabis users had higher triglyceride levels and lower HDL cholesterol compared with non-users in an HIV cohort, independent of ART type [21]. Dyslipidemia is already prevalent in HIV-associated lipodystrophy, and tesamorelin modestly reduces triglycerides as a secondary effect in its trials [3]. Adding cannabis-associated dyslipidemia creates another monitoring obligation.

Smoking Route and Pulmonary Considerations

Smoked cannabis delivers combustion products that can worsen pulmonary function. PLWH already face elevated pneumonia risk [22]. For patients on tesamorelin who choose to use cannabis, vaporized or oral routes are preferable on pulmonary grounds, independent of the GH-axis considerations.

Can You Drink Alcohol on Egrifta (Tesamorelin)?

Alcohol shares some mechanistic overlap with cannabis regarding the GH axis. Acute ethanol ingestion suppresses GH secretion, likely through increased hypothalamic somatostatin release, in a manner similar to the THC-mediated pathway [23]. Chronic heavy alcohol use is associated with low IGF-1 and overt GH deficiency [24].

The Egrifta SV label does not specifically address alcohol. Standard clinical practice for patients on any GH-axis agent is to limit alcohol to moderate intake (up to 1 drink/day for women, up to 2 for men per CDC definition) and to avoid binge drinking on injection days [25]. The metabolic hepatotoxicity risk is a separate concern in HIV patients with underlying hepatic steatosis, which is common in HIV-associated lipodystrophy [19].

Key Safety Signals to Watch

Patients combining tesamorelin with cannabis should alert their care team if they experience:

• Unexpected weight gain or abdominal fullness suggesting VAT rebound
• Fasting glucose above 126 mg/dL or HbA1c above 6.5% (new-onset diabetes threshold per ADA 2024 Standards of Care) [26]
• Fluid retention, joint pain, or carpal tunnel symptoms, which may indicate supraphysiologic GH effect if other axis suppressors are removed abruptly
• Persistent fatigue that may reflect inadequate IGF-1 response

The Endocrine Society guideline for GH therapy states: "IGF-1 should be maintained within the age- and sex-specific normal range; values consistently above the upper limit of normal require dose reduction" [4]. The same principle applies in reverse; consistently below-normal IGF-1 on a therapeutic dose warrants an investigation into suppressive co-exposures.